Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Rockwell Medical Q3 2026 Results: Net Loss of $2.32M, Loss Widens

Rockwell Medical reported net sales of $19.1 million for Q3 2026, a 20% increase over the prior year, though net loss widened to $2.3 million. The company maintained a cash and investment position of $22.5 million while managing a total accumulated deficit of $408.1 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue19.115.9
Gross profit3.12.3
Net income-2.3-1.8
EPS (diluted, $ a share)$-0.59$-0.49

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+20.1%
Gross margin16.3%
Operating margin-11.6%
Source

10-Q filed with the SEC, NASDAQ: RMTI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Rockwell Medical, Inc.: key numbers

Share price
$6.76Close, Nov 16
Market cap
$27.2M
Shares outstanding
4.03MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Rockwell Medical, Inc.

All →
6:12 AM ET 8-K
Financial Results

Rockwell Medical Financial Results

Rockwell Medical reported third quarter 2026 net sales of $19.1 million, a 20% increase year-over-year, driven by higher volumes from existing and new customers. The company highlighted its pending transformational acquisition of Vantive's hemodialysis business, which is projected to generate annual revenue between $400 million and $450 million.

Term
Q3 2026

“We have maintained solid upward momentum across our business, driven by robust market demand and disciplined execution. Our third quarter 2026 net sales grew 20% year-over-year, reflecting strong customer adoption and market validation of our products.”

Mark Strobeck, Ph.D., President and Chief Executive Officer
4:50 PM ET 8-K
M&A Deal

Rockwell Medical Signs $125M M&A Deal with Vantive Limited

Rockwell Medical has entered into a definitive agreement to acquire Vantive Limited's global in-center hemodialysis business for a base purchase price of $125 million. The acquisition includes manufacturing facilities in Italy, operations in 35 jurisdictions, and a product portfolio spanning concentrates, machines, and water treatment systems. The deal is expected to transform Rockwell into a global provider with projected annual revenues between $400 million and $450 million.

Value
$125M
Counterparty
Vantive Limited

“Acquiring Vantive’s hemodialysis assets and associated operations represents a transformative step in Rockwell Medical’s evolution and directly advances the strategy we have been executing over the past several years.”

Mark Strobeck, Ph.D., President and Chief Executive Officer at Rockwell Medical

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.